The federal government has decided against procuring a protein-based COVID-19 vaccine for the fall immunization campaign — despite it being the only type that some immunocompromised people say they have been able to tolerate.
While the mRNA vaccines made by Pfizer and Moderna are effective at preventing severe illness, hospitalization and death, some people with autoimmune diseases say the jabs can come with a terrible trade-off.
Comments closedLinda Wilhelm, 64, of Bloomfield, N.B., is planning a road trip to the United States. But it’s not to go sightseeing or shopping.
Wilhelm, who suffers from severe rheumatoid arthritis, hopes to get the updated Novavax COVID-19 vaccine, which won’t be available in Canada as part of the fall vaccination campaign, unless provinces and territories order doses on their own.
Wilhelm, president of the Canadian Arthritis Patient Alliance and a member of the Canadian Immunocompromised Advocacy Network, says the protein-based vaccine is a better option for immunocompromised people like her than the more common Pfizer-BioNTech and Moderna mRNA vaccines. She says she feels “expendable” and urges the federal government to reconsider.
Less than two months ago, the network wrote to numerous federal, provincial and territorial officials, calling for improved access to Novavax and increased awareness.
Comments closedExperts and patient groups have warned that the high cost of private Covid vaccinations could exacerbate health inequalities and leave those more at risk from the virus without a vital line of defence.
Both high street chain Boots and pharmacies that partner with the company Pharmadoctor are now offering Covid jabs to those not eligible for a free vaccination through the NHS, with the former charging almost £100 for the Pfizer/BioNTech jab.
While Pharmadoctor says each pharmacy sets its own prices, it suggests the Pfizer/BioNTech jab will set customers back £75-£85, while the latest Novavax jab will cost about £45-£55.
Comments closedCanadians raced to get vaccinated against COVID-19 in the first years of the pandemic, but data suggests there’s far less of a rush to get the latest shots available this fall.
Federal figures show only 15 per cent of the population aged five and up had received an updated vaccine by Dec. 3. And while older age groups had higher uptake rates, more than half of higher-risk older adults still hadn’t gotten a dose by early December, either.
Comments closedCOVID-19 vaccine maker BioNTech (22UAy.DE) aims to start production at its mRNA vaccine factory site in Rwanda in 2025, company officials said on Monday, the first foreign company mRNA vaccine manufacturing site on the continent.
The German company’s first modular factory elements, based on shipping containers, were delivered to the Kigali construction site in March and were then assembled into so-called BioNTainers.
Comments closedErin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax Covid-19 vaccine in mid-October soon after it was finally recommended in the United States. Like many people with autoimmune diseases, she wants to protect herself from a potentially devastating Covid infection.
Kissane’s autoimmune arthritis seems to make her susceptible to unusual vaccine side effects. After getting an mRNA booster last year, her joints ached so painfully that her doctor prescribed steroids to dampen the inflammation. She still considers the mRNA vaccines “miraculous,” knowing Covid could be far worse than temporary aches.
Comments closedThe country’s national vaccine advisers are recommending Canadians get another COVID-19 booster shot this fall, with updated vaccines expected in the months ahead.
The next round of vaccines will likely be monovalent — meaning they will specifically target the Omicron family of sub-lineages that are still circulating globally, the National Advisory Committee on Immunization (NACI) said Tuesday.
Leave a comment